Purpose. With an increase in the numbers of bacterial isolates resistant to first-line antibiotics, there has been a revival in the use of older drugs including fosfomycin with novel mechanisms of action. We aimed to investigate the prevalence and genotypic nature of fosfomycin resistance in Escherichia coli from urinary tract infections (UTIs) using the various methods available in the clinical microbiology laboratory.
INTRODUCTION
Globally, increasing numbers of infections are caused by bacteria resistant to current antibiotics [1] . As there is a lack of new antibiotics in development, the revival of older drugs with distinct methods of action has been proposed as a short-term solution [2] . One such drug is fosfomycin, a phosphonic-acid derivative cell wall inhibitor with a novel mode of action and a broad spectrum of activity [3] . In Enterobacteriaceae, fosfomycin is taken up by mimicking the natural substrates of two nutrient transport uptake systems, GlpT and UhpT (inducible in the presence of glucose 6-phosphate) [4] , systems which require cyclic adenosine monophosphate (cAMP), cAMP-receptor protein complexes and activator genes such as uhpA [5] [6] [7] . Once in the bacterial cytosol, fosfomycin acts as a phosphoenolypyruvate analogue preventing the initial step of cell wall synthesis, via inhibition of MurA [4] , leading to the prevention of peptidoglycan biosynthesis and cell death [8] . As fosfomycin acts prior in the biosynthesis pathway to other cell wall inhibitors such as b-lactams and glycopeptides, it is not inhibited by resistance determinants which act against these drugs such as extended spectrum beta-lactamases [9] .
Historically the most commonly documented mechanism of fosfomycin resistance has been impaired transport of fosfomycin into the cytoplasm, due to mutations in structural or regulatory genes of the nutrient transport systems [10] ; for example in Escherichia coli, these are insertions, deletions or mutations leading to amino-acid changes in glpT, uhpT or uhpA. Alternatively, mutations in genes encoding adenylcyclase (cyaA) and phosphotransferses (ptsI) are known to decrease intracellular levels of c-AMP, reducing the expression of glpT and uhpT and, consequently, intracellular fosfomycin levels [11] . Mutations in the gene encoding the drug target MurA, particularly those that confer amino acid changes in the active site and Cys115 residue, have been demonstrated to decrease the susceptibility of the organism by reducing its affinity for fosfomycin [12] [13] [14] ; however, these are rare in nature and may impair bacterial fitness [10] . Over-expression of murA has also been found both in mutants selected in vitro and in clinical isolates. It has been suggested that this mechanism acts to saturate fosfomycin molecules, thereby allowing normal cellular function [15, 16] .
A final and, perhaps emerging, mechanism of resistance is the acquisition of enzymes that can inactivate fosfomycin by catalysing the opening of its oxirane ring [17] [18] [19] .
Data from multiple studies have shown that exposure to fosfomycin in vitro rapidly selects resistant mutants, at a frequency of 10 À7 -10 À8 [20, 21] . However, mutants selected experimentally are typically physiologically impaired, with decreased growth rates in culture media and urine when compared to wild-type strains [20] . It is also thought that fosfomycin-resistant isolates may have a reduced ability to adhere to uroepithelial cells or catheters, and to have a higher sensitivity to polymorphonuclear cells and serum complement killing [22] . Therefore, it has been speculated that despite the rapid development of resistance in vitro, significant biological fitness costs prevent the establishment and propagation of resistant strains in vivo [2, 20] .
In Japan, Spain, Germany, Austria, France, Brazil, North America and South Africa, fosfomycin has been used extensively for >30 years [23] . In these regions a soluble salt form called fosfomycin-tromethamine (typically given as a single 3 g oral dose) is widely used in the treatment of uncomplicated urinary tract infections (UTIs) [24] . Until recently, fosfomycin-trometamol was not distributed or commercially available in the UK; thus, any products used were imported, and therefore unlicensed. Despite this, the National Health Service recorded a ten-fold increase in fosfomycin-trometamol prescriptions from 100 to 1000 between 2012 and 2013 [25] , and a further increase to 2400 prescriptions in 2014 [25] .
Renewed interest in fosfomycin has been for treatment of multi-drug-resistant organisms causing UTIs where oral therapy choices may be limited. Considering these factors and the possibility of introducing fosfomycin preparations into our formulary, our first aim was to determine the proportion of organisms isolated from routine UTI cultures deemed to be resistant to fosfomycin. In doing so the various methods of measuring susceptibility to fosfomycin available to our clinical laboratory were assessed, and their relative merits considered. The second aim was to investigate the mechanisms of fosfomycin resistance.
METHODS

Bacterial isolates
Between July and August 2014, 2800 urine specimens received as part of standard patient care (over 18 days in total) at Northampton General Hospital, a large 700-bed tertiary hospital in the UK, were collected. Subsequent analysis of isolates and susceptibility testing followed the laboratory work-flow and methodologies used for clinical investigation of specimens in this trust. Each was examined for signs of infection using Iris IQSprint microscopy and those specimens meeting conventional clinical criteria were cultured using the MAST Uri system (n=1000) as per the manufacturer's instructions. The susceptibility status of each cultured isolate to fosfomycin was determined using a 96-well 'breakpoint' agar plate containing 32 µg fosfomycin ml À1 supplemented with glucose 6-phosphate at 25 µg l
À1
as provided by MAST, and a presumptive species identification was carried out by determining the colour of colonies growing on MAST CUTI chromogenic agar. A total of 62 isolates putatively identified as fosfomycin-resistant E. coli then had their species confirmed using matrix-assisted laser desorption ionization/time-of-flight (MALDI-TOF) MS and were retained for further study. E. coli J53-2 (NCTC 50167) was used as a fosfomycin-susceptible control; E. coli NCTC 10418 was used as a quality control for susceptibility testing; and E. coli MG1655 (ATCC 700926) was used as a reference strain for genome comparisons.
Antimicrobial susceptibility testing
The MICs of an extended panel of antimicrobials were determined using the BD Phoenix automated microbiology system with antimicrobial susceptibility testing panel UNMIC-409 as per the manufacturer's instructions. Fosfomycin MICs were further determined using fosfomycin E-tests (bioM erieux) and using the agar dilution method following the British Society of Antimicrobial Chemotherapy (BSAC) guidelines [26] .
Whole genome sequencing and post-sequencing analysis Isolates consistently considered resistant by all susceptibility testing methods were genome sequenced by MicrobesNG using an Illumina MiSeq system. Velvet (v.1.2.10) [27] was used for de novo assembly of the genomes, and Prokka (v.1.11) [28] used for annotation. Reads were also analysed using the 'nullarbor' pipeline (v.1.2) using a standard virtual machine on the MRC CLIMB framework. Pan genomes were generated using 'roary' (v.8.0), single nucleotide polymorphisms called with 'snippy' (v.3.0) and antibiotic resistance genes and mutations identified using 'ARIBA' (v.2.8.1). Trees were visualized with 'Phandango'. All packages used default parameters unless stated otherwise. The Centre for Genomic Epidemiology (http://www.genomicepidemiology.org/) provided software for interrogation of genomes for multi-locus sequence type (MLST), E. coli serotype, plasmid replicons and resistance-associated genes (ResFinder); the Comprehensive Antibiotic Resistance Database (CARD) was additionally used to identify resistance determinants [29] .
RESULTS
Fosfomycin resistance in UTI isolates using the MAST Uri system From 1000 UTI culture-positive isolates, 657 were confirmed as E. coli and 62 (9.5 %) were deemed fosfomycinresistant using breakpoint plates on the MAST Uri system, with growth on !80 % of the culture well indicating an MIC>32 µg ml
À1
.
Determination of fosfomycin MICs
Fosfomycin MICs using BD Phoenix Using an automated micro-broth dilution method (BD Phoenix), 53/62 E. coli isolates (85.5 %) were found to have fosfomycin MICs of <16 µg ml
À1
, three isolates (4.8 %) had an MIC of 32 µg ml À1 and six isolates (9.7 %) had an MIC of 64 µg ml
. Therefore, only six isolates showed concordance with data from the MAST Uri system, and were deemed resistant using BD interpretative software (Epicentre) with EUCAST breakpoints (>32 µg ml À1 ) [30] .
Fosfomycin MICs using E-tests
Due to the discrepancy between micro-broth dilution and breakpoint plate MIC methods, E-tests were used as an alternative method for measuring fosfomycin MICs. Two susceptible control strains, E. coli J53-2 and E. coli NCTC-10418, grew with definitive zones of inhibition, revealing MICs of 0.25 µg ml À1 . Similarly, six selected isolates deemed resistant using the MAST Uri system but susceptible using the micro-broth dilution (BD Phoenix) were found to be sensitive to fosfomycin using E-tests; each grew with a single defined zone of inhibition and MICs ranging from 0.19 to 0.75 µg ml À1 (Table 1 ).
All the isolates deemed resistant by both the MAST Uri system and BD Phoenix were also categorized as resistant using E-tests. Despite agreement of a resistance interpretation between the three methods, there was little concordance between the specific MICs determined by E-tests and the micro-broth dilution method (Table 1) .
Of note was the difficulty in reading and interpreting Etests. In each test a small number of single colonies were observed within the clearance zone. As recommended by others who have recorded the same phenomenon [31] , these colonies were excluded from the E-test interpretation. Five isolates had a visible 'intermediate' zone of noticeably less dense growth, presenting two possible interpretations. Due to the semi-confluent nature of the growth in these regions they were not included in the zone of inhibition when reading the strips (Table 1) .
Investigation of fosfomycin MICs using modified agar dilution
To further explore the differing growth phenotypes when using E-tests, a modified agar dilution method was used in which colonies were streaked on agar containing different concentrations of fosfomycin and their growth was observed. For the control organisms and six fosfomycin-susceptible organisms as determined by Phoenix/E-tests, either no growth, or single colony/scanty growth was observed on agar containing a low concentration of fosfomycin ( 16 µg ml
À1
). Each of the nine resistant isolates cultured on a low concentration of fosfomycin produced uniform colony morphologies; when grown in the presence of higher concentrations of fosfomycin, however, each produced a 'dual colony' growth phenotype.
Characterization of selected E. coli isolates Whole genome sequencing (WGS) was used to characterize eight of the consistently fosfomycin-resistant isolates and two, randomly selected susceptible isolates. Fosfomycin resistance was present in several different E. coli sequence types (STs) (six different STs were seen in the eight resistant isolates, ST131 was the only ST seen more than once) indicating that resistance was not distributed due to clonal expansion of one strain ( Fig. 1 and Table 2 ). The E. coli STs found in this study include those previously reported as common in UTI isolates in the UK: ST69, 73, 95 and 131 [32] . Each of the ten isolates was further characterized by investigating their antibiogram, determined from their susceptibility profile to antimicrobials used in the treatment of UTIs, and by interrogating WGS for genes and mutations known to confer antimicrobial resistance (Table 2) . Ampicillin resistance was detected in 8/10 isolates, accompanied with the in silico detection of bla TEM-1B . Sulfamethoxazole resistance in 5/10 isolates corresponded with the detection of a dfrA gene and with either sul1 or sul2. Aminoglycoside resistance genes were identified in five of the isolates; of note was an ST131 isolate possessing the gentamicin resistance gene aac(3)-IId along with a ciprofloxacin resistanceconferring mutation in gyrA.
The in silico analysis also showed the presence of many common Enterobacteriaceae plasmid replicons, including those of incompatibility groups IncF, IncQ, IncX1 and IncB/O/K/Z, and plasmids from group Col and Col156. Using CARD, Resfinder and manual searches, no fos-like genes were detected in any of the strains, suggesting an absence of known plasmid-based transferrable fosfomycin resistance genes in the resistant isolates.
Amino acid variation in proteins associated with fosfomycin resistance
For each of the ten sequenced isolates, amino acid changes or mutations in known fosfomycin resistance genes murA, glpT, uhpT, uhpA, ptsI and cyaA were identified from the WGS using E. coli MG1655 as a reference (Table 3) . No murA changes were identified in any of the fosfomycin-resistant isolates, while a single substitution of Val389Ile was found in susceptible isolate MU723432.
All sequenced isolates were found to have a Glu448Lys change in GlpT when compared to strain MG1566. Fosfomycin-resistant isolate MU721372 had an additional three substitutions of Leu297Phe, Thr348Asn and Glu443Gln, although susceptible isolate MU724857 also had a second GlpT change of Ala16Thr.
No amino acid changes in the sequence of UhpT were identified in fosfomycin-susceptible isolates; however, 5/8 resistant isolates had changes in this protein. In MU720214, both uhpT and uhpA were absent. Comparative analysis against other E. coli genomes showed the presence of a phage integrase gene adjacent to the uhpT-uhpA region within the assembled contig, suggesting a deletion event.
Isolate MU720350 had two amino acid changes at positions 31 and 39 predicted to confer premature stop codons leading to a truncated protein; four strains had a Glu350Gln amino acid substitution; and MU723240 had additional substitutions of Tyr32Asn and Arg325Leu.
Only three isolates had changes in the uhpA gene, a deletion in MU720214, an Arg46Cys substitution in susceptible isolate MU724857, and substitutions Arg14Gly and Ala110Ser in fosfomycin-resistant isolate MU721372 (Table 3) . When examining genes that affect levels of intracellular cAMP, all the isolates had the substitution of Arg367Lys in PtsL and Asn142Ser in CyaA when compared to MG1655; both changes are well represented in many E. coli isolates. Two further substitutions were identified in PtsL, Val25Ile in two of the resistant isolates (MU723051 and MU723320) and Ala306Thr in one resistant (MU720214) and one susceptible E. coli isolate (MU724857). The amino acid sequences of CyaA in each isolate fell broadly into two groups, those with a single Asn142Ser change when compared to MG1655 (n=4), and those with three or more additional amino acid substitutions (Ser352Thr, Ala349Glu, Ser356Lys, Gly359Glu and Ile514Val) (n=5, Table 3 ), both containing susceptible and resistant isolates. These amino acid substitutions appeared to correlate more closely with ST than with fosfomycin susceptibility status and were found commonly in other E. coli strains.
DISCUSSION
To investigate the extent of fosfomycin resistance in UTI isolates from routine clinical specimens, different methods available to distinguish susceptible and non-susceptible isolates using clinical laboratory protocols were explored. Use of 'breakpoint' plates on the MAST Uri system for highthroughput screening determined the prevalence of resistance (MIC!32 µg ml
À1
) in E. coli isolates as 12 %; this rate is significantly higher than previously documented [33] [34] [35] . However, on further examination using automated microbroth dilution, only nine of these isolates were resistant (MIC!32 µg ml
). Furthermore, if Clinical and Laboratory Standards Institute guidelines had been applied none of the isolates would be deemed resistant, as each had an MIC below the breakpoint according to this scheme (susceptible 64, intermediate=128 and resistant!256 µg ml À1 ) [36, 37] . Susceptibility interpretations from the E-test method corroborated the findings from micro-broth dilution, concordantly differentiating isolates deemed fosfomycin-susceptible and resistant. Therefore, both these methods agree that only 1.3 % of E. coli within the study should be regarded as fosfomycin-resistant using current definitions, a prevalence more in line with findings of previous studies both globally and within the UK [37, 38] . The high prevalence of resistance recorded by the MAST Uri system reflects a large number of false positive results (53/62) given the interpretive criteria followed. Whilst changes to fosfomycin susceptibility can occur relatively rapidly in vitro it is infeasible that a significant number of isolates initially identified as resistant would have reverted to susceptibility in the time window of the laboratory investigations. However, there may also have been some false-susceptible results given the methodologies we used.
In the collection period, fosfomycin was not used in the hopsital trust or by community pharmacists in the area, and therefore patient exposure to the drug is likely to have been low, and a 1.3 % rate of resistance probably reflects spontaneous mutants which are in the wider population of E. coli. Given the reports of fosfomycin resistance incurring a significant fitness cost [10, 20] this level may be higher than expected given the probable lack of direct selection in this population.
Lu et al. [39] discussed the usefulness of disc-diffusion assays in distinguishing fosfomycin-susceptible and resistant isolates despite reports of single colony generation within the zone of inhibition [31] . A beneficial next step might be to directly compare micro-broth dilution and Etest methods to disc-diffusion assays to establish the most robust and practical method for determining fosfomycin susceptibilities within a clinical laboratory setting and to assess the reproducibility of each method for those deemed susceptible and resistant. Interpretation of E-tests was obfuscated by an intermediate zone of growth, resembling in appearance a 'small' colony phenotype observed at higher concentrations of fosfomycin when isolates were streaked onto plates. A similar 'dual colony' phenomenon in the presence of fosfomycin has been described by Tsuruoka et al., who reported differences in growth and carbohydrate uptake between colony types [21] . In the present study, these distinct phenotypes were found to be transient and inconsistent, large and small colonies going on after passage to produce daughter colonies of both phenotypes in the presence of higher concentrations of fosfomycin (data not shown), further hindering interpretation of susceptibility testing.
In silico MLST and whole genome comparison of the fosfomycin-resistant E. coli showed that the isolates were of diverse STs, and that resistance and plasmid profiles differed in each isolate. Therefore, resistance had not disseminated in this population due to expansion of one clone. Examination of the mechanisms of resistance found no evidence for mobile elements being involved in fosfomycin resistance, and the absence of any plasmid-located fos genes suggests that resistance in these E. coli was due to chromosomal mutations. When examining sequences of genes known to contribute to fosfomycin resistance, no two isolates had the same set of substitutions or mutations. As in other studies, changes in GlpT and UhpT/UhpA transport systems responsible for uptake of fosfomycin were the most commonly identified; 6/8 resistant organisms possessed amino acid changes or deletions within these systems that were absent in the susceptible strains. This included complete deletion of the uhpT/uhpA region, location of a premature stop codon predicted to lead to a truncated UhpT protein, and the commonly reported UhpT substitution Glu350Gln [14, 40] , all speculated to result in reduced uptake of fosfomycin. Substitutions in GlpT were less common in this study than in other recent reports, with only a single isolate (MU721372) accumulating many changes in this region. Of note is the Glu448Lys substitution, identified previously in other fosfomycin-resistant isolates [14] . This change was identified in all the sequenced isolates when compared to MG1655, including those deemed susceptible, but was not found during a search of an extended panel of sequenced E. coli isolates submitted to GenBank. This suggests either that this substitution does not confer resistance to fosfomycin, contradicting speculation by others [14] , or that it acts to reduce susceptibility, perhaps below our defined breakpoints in the absence of other changes within the protein. It may be that low-level changes to susceptibility account for why some isolates were deemed resistant using screening with the MAST Uri system, whilst remaining sensitive using other testing methods.
Only a single substitution (Val389Ile) was identified in MurA within the sequence of one of the susceptible isolates. Although this modification has been reported by others in fosfomycin-resistant isolates [40] , its location outside the active site of this enzyme means its role in resistance is ambiguous. The role of changes in the CyaA and PtsI proteins in this study is less clear. The amino acid sequence of CyaA appeared to divide into two groups, both with substitutions which can be found in other fosfomycin-susceptible E. coli. This suggests that these changes may be unrelated to fosfomycin susceptibility but may correspond to the E. coli phylogeny.
While many of the substitutions identified in this study have previously been linked to fosfomycin resistance by others, our detection of amino acid changes in both susceptible and non-susceptible strains raises doubts regarding their contribution to fosfomycin resistance. Mutations within the transport systems could be further investigated by growing these organisms on minimal media with or without glucose 6-phosphate or glycerol 3-phosphate to elucidate their functional status.
The use of fosfomycin for treatment of UTIs and other infections is likely to increase. In this study, the prevalence of fosfomycin resistance in E. coli isolated from UTIs was found to be relatively low and resistant isolates were divergent. The identification of chromosomally based changes in genes associated with fosfomycin susceptibility, and the absence of fos genes on conjugative plasmids indicates that resistance in these isolates was not transferrable, and that co-location with other resistance genes did not appear to lead to co-selection. Therefore, in this setting fosfomycin remains a useful agent in the treatment of UTIs, equipping us with an extra option for difficult-to-treat UTIs and providing an alternative to drugs such as carbapenems which may drive selection of resistant organisms further. Current methods to identify fosfomycin-resistant E. coli isolates in urine can give very different results, so there is a need for more consistency to accurately define real rates of resistance, which is important in monitoring any evolution of resistance as fosfomycin use is likely to increase. 
